Table 2.
Clinical performance of the Abbott (Architect SARS-CoV-2 IgG) and DiaSorin (Liaison SARS-CoV-2 S1/S2 IgG) serological assays in an Australian cohort
| Characteristic | May 2020 community period prevalence ∼0.03%a (n=1972) [95% CI] |
August – October 2020 community period prevalence ∼0.4%b (n=792) [95% CI] |
||
|---|---|---|---|---|
| Abbott | DiaSorin | Abbott | DiaSorin | |
| Proportion of cases detected (true positive/composite positivec) | 100% (1/1) | 100% (1/1) | 92.7% (38/41) | 95.1% (39/41)d |
| Positive predictive valuee (true positive/all positive) | 8.3% (1/12) | 2.7% (1/37) | 90.5% (38/42) | 67.2% (39/58) |
CI, confidence interval (Clopper–Pearson).
a
Period prevalence January–May 2020 and b period prevalence January–October 2020 determined according to RT-PCR confirmed case count, Victorian Department of Health and Human Services.
c
Composite positive case numbers = those samples testing positive in either assay and then confirmed either by microneutralisation or by surrogate virus neutralisation.
d
One equivocal sample counted as positive.
e
As compared to microneutralisation or testing at the reference laboratory by surrogate virus neutralisation.